OM
CBIO

Opaleye Management’s Crescent Biopharma CBIO Stock Holding History

Opaleye Management’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$23.7M Buy
1,319,351
+6,736
+0.5% +$132K 2.15% 12
2026
Q1 		$24.1M Buy
1,312,615
+134,315
+11% +$1.54M 3.18% 9
2025
Q4 		$14M Buy
+1,178,300
New +$15M 1.84% 14

Other funds holding CBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Opaleye Management's CBIO Position: Q2 2026 in Review

Opaleye Management increased its Crescent Biopharma (CBIO) stake by 0.51% in Q2 2026, buying an estimated $132K and bringing the position to 1,319,351 shares worth $23.7M. The position accounts for 2.15% of the portfolio, ranked #12.

Opaleye Management first reported a position in CBIO in Q4 2025 and has held it in 3 quarters since. The position peaked at $24.1M in Q1 2026. 82 funds tracked by Wall St. Rank hold CBIO as of Q2 2026.

  • Opaleye Management held 1,319,351 shares of Crescent Biopharma worth $23.7M as of Q2 2026.
  • Opaleye Management bought 6,736 Crescent Biopharma shares in Q2 2026, an estimated $132K.
  • Crescent Biopharma made up 2.15% of Opaleye Management's portfolio in Q2 2026, its #12 holding.
  • Opaleye Management first reported a position in Crescent Biopharma in Q4 2025 and has held it in 3 quarters since.
  • Opaleye Management's Crescent Biopharma position peaked at $24.1M in Q1 2026.
  • 82 funds tracked by Wall St. Rank held Crescent Biopharma as of Q2 2026.

Based on Opaleye Management's 13F filing for Q2 2026, filed 14 Aug 2026.